NCT00474799View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of MNS075 (Intranasal Morphine)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Healthy
Interventions
DRUG

MNS075

MNS075 7.5mg q1h MNS075 15mg q3h

Trial Locations (1)

78754

CEDRA Corporation, Austin

Sponsors
All Listed Sponsors
lead

Javelin Pharmaceuticals

INDUSTRY